THU0665 Can One Give Up Basdai in Favor of Asdas in Monitoring Spondyloarthritis Patients on Biologics?

doi 10.1136/annrheumdis-2017-eular.5326
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Preliminary Definitions of ‘Flare’ in Axial Spondyloarthritis, Based on Pain, BASDAI and ASDAS-CRP: An ASAS Initiative

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2016English

Eligibility Criteria for Biologic Disease-Modifying Antirheumatic Drugs in Axial Spondyloarthritis: Going Beyond BASDAI

RMD Open
RheumatologyAllergyImmunology
2020English

Captopril Test Can Give Misleading Results in Patients With Suspect Primary Aldosteronism

Hypertension
Internal Medicine
2007English

Fusion Gene Addiction: Can Tumours Be Forced to Give Up the Habit?

Journal of Pathology
Forensic MedicinePathology
2017English

Ambulatory Blood Pressure Monitoring in Patients With ST- Elevation Myocardial Infarction: One Year Follow-Up Study

International Journal of Research in Medical Sciences
2019English

Biologics in Patients With Skin Diseases

Journal of Allergy and Clinical Immunology
AllergyImmunology
2017English

Bowel Involvement in Patients With Spondyloarthritis

Nauchno-Prakticheskaya Revmatologiya
RheumatologyAllergyImmunology
2015English

Should We Give Up Hormone Treatment in Menopause?

Turk Jinekoloji ve Obstetrik Dernegi Dergisi
GynecologyObstetrics
2013English

AB1449-HPR Patient Factors Contributing to and Shared Decision Making in Starting/Switching Biologics Spondyloarthritis

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy